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In 2007, a report by the International Finance Corporation (IFC), - part of the World Bank 
Group - entitled The business of health in Africa: Partnering with the private sector to 
improve people’s lives, argued that expanding the private health sector is good for both 
investors and country populations. Whilst acknowledging the need for appropriate regulation, 
the report encouraged governments and external funders to facilitate private sector 
expansion through more business-friendly policies and to subsidise private sector initiatives.  
This review was commission by the Regional Network for Equity in Health in East and 
Southern Africa (EQUINET) to explore the implications of expansion of the private for profit 
health sector for equitable health systems in East and Southern Africa. It summarises the 
rationale behind the IFC’s recommendations. It then explores whether there are signs of 
increasing for-profit private sector activity in the region, along the lines suggested by the IFC. 
The report then identifies issues of concern on private for profit activity in the health sector.  
This is an initial scoping exercise based on a desk review of the predominantly grey 
literature on for-profit private sector activity in the health sectors of East and Southern Africa. 
Lack of available data means that the paper suffers from several data limitations. Further 
research is needed on the different for-profit private activities in the health systems of the 
region, to better understand their impact, particularly of the informal, for-profit private sector.  
 
The IFC report argues for the expansion of the private sector in Sub-Saharan Africa as: 
1. Already, 60% of health financing is from private sources. 
2. Also, 50% of health expenditure is spent on private providers. 
3. Rapid economic growth is set to expand the African middle-class, increasing the capacity 
to pay for care and consequently the demand for good quality services. 
4. Demand is also increasing due to new developments in the health sector, such as the 
emergence of generic drugs, low-cost insurance and medical tourism. 
5. The public sector is unable to meet even current demand because of a shortage of 
capital and human resources and problems with efficiency and quality. 
6. External funding is also stagnating. 
7. The private health sector has the means to address this gap and offers good returns on 
investment, particularly as stability and good governance grows on the continent. 
8. Both businesses and country health systems can benefit from a stronger private sector. 
 
With respect to financing, the literature reveals the entry of new foreign and domestic 
private investors into the health care sector, as well as the provision of new types of loans, 
both directly or indirectly through local banks. The new Health Insurance Fund and Africa 
Health Fund bring together development funding (from governments and external funders) 
with funds from business to provide ‘seed’ money for new private health care initiatives. With 
respect to ownership, emerging enterprises are either entirely private (sometimes from 
privatisation of existing public services) or public-private partnerships based on contracts.  
 
Three components of the health sector which this report was able to investigate are 
hospital care, risk-pooling arrangements and pharmaceuticals (data constraints precluded 
investigating other dimensions). With respect to hospitals, there seems to be a trend towards 
high-end, ‘boutique’ hospitals that target the high-income, expatriate, diplomatic, NGO and 
medical tourism markets. Another trend is towards high-volume hospitals that serve middle- 
and low-income patients. With respect to risk-pooling arrangements, private health insurance 
is being strongly promoted in several countries, like South Africa. Lastly, pharmaceutical 
multinationals reportedly see future growth resting on expansion into Africa. 
 
These developments indicate that: 
 Even very poor or countries with recent conflict have received new investments in the 




 There is more private sector activity in some countries, eg: Kenya, Uganda, Tanzania. 
 The private sector-oriented NGO, PharmAccess, has wide influence, with involvement in 
two funds investing in private health care and various private health insurance initiatives. 
 Several South African companies are expanding into the rest of the region.  
 
Backing for an increased role for the for-profit private health emanates not only from the IFC, 
but also from other international agencies and initiatives such as the World Health 
Organisation (WHO), USAID, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and 
the Bill and Melinda Gates Foundation, as well as Western governments, such as the United 
Kingdom and the Netherlands. Governments within east and southern Africa have also 
encouraged private sector investment. The South African experience, on the other hand, 
raises questions about the beneficial impact of the for-profit private sector. In South Africa, 
de-regulation in the late 1980s saw the proliferation of private health insurers, fragmentation 
of risk pools, reduced income and health cross-subsidies, rising costs for health insurance 
premiums, rising fees charged by private providers (especially by hospitals), declining 
coverage, increased vertical integration (resulting in declining competition), capturing of 
public subsidies by the private sector and skilled health professionals being attracted away 
from the public sector. These trends have proved very difficult to reverse during the 2000s. 
 
This experience challenges the assumptions behind the IFC report, especially with respect 
to the impact of the private sector on health care coverage and the integrity of the health 
system. It suggests it is unwise for governments (and external funders) to encourage the 
unfettered expansion of the private for-profit sector without, first, considering both the 
benefits and the unintended consequences and, second, putting in place appropriate 
regulation (together with the capacity to evaluate and enforce it). Governments need to 
consider features that may lead to private sector expansion not supporting social objectives:  
 Still limited evidence on the impact of the for-profit private sector, not least because of 
limited information from private enterprises, making it difficult to monitor their impact. 
 Weak policy frameworks and limited regulation of the private sector making it difficult for 
governments to manage and oversee private sector expansion. 
 Contractual relationships often unfavourable to governments in terms of the sharing of 
risk and difficulties for government to penalise companies that violate contracts. 
 Private sector capture of public subsidies.  
 Escalating costs associated with private sector expansion, even where private sector 
initiatives have been designed to cut costs. 
 Increasing consolidation of companies, verticalisation of components of the health care 
market and the entry of large foreign companies has so far restricted competition. 
 Erosion of the public sector associated with increased private sector activity through, for 
example, the fragmentation of risk pools and the brain drain of public sector personnel. 
 
Given these concerns Ministries of Health need to highlight both benefits and pitfalls of 
encouraging for-profit private sector provisioning in economic growth policies and assess the 
opportunity costs of supporting the for-profit private health sector as opposed to developing 
the public health system. This calls for health impact assessments before investments, 
especially where government subsidies or external funds are involved, evaluation of the 
impact of  private sector activities on core social objectives and monitoring of these 
investments. Comprehensive policies on the private sector need to be developed, together 
with a robust regulations and state capacities to monitor private sector activity and enforce 
regulations and sanctions. Governments need to act firmly against the development of 
monopolies and unethical business practices and prioritise activities that improve coverage 
in rural areas and low-income populations. For Ministries to gain support for these 
approaches, especially amongst external funders, it is essential that they provide a good 
quality alternative to for-profit private health care. This requires injecting adequate resources 







A 2009 discussion paper of the Regional Network for Equity in Health in East and Southern 
Africa (EQUINET) on the commercialisation of the health sector in East and Southern Africa 
concluded that, overall, new private investment in the region had been minimal, at least until 
2007 (Ruiters and Scott 2009). Botswana, Mauritius, Namibia and South Africa appeared to 
be the growth points for private investment, with the latter clearly the dominant country. 
Other countries experienced very low, uneven and sometimes declining levels of investment. 
 
In 2007, however, a report was published by the International Finance Corporation (IFC) 
which is part of the World Bank Group. Entitled The Business of Health in Africa: partnering 
with the private sector to improve people’s lives, the report argued that expanding the private 
health sector would be good for both investors and country populations (IFC 2007). Whilst 
acknowledging the need for appropriate regulation, the report encouraged governments and 
external funders (donors) to facilitate private sector expansion through more business-
friendly policies and subsidisation of private sector initiatives.  
 
This report was commissioned by EQUINET to highlight ‘policy challenges of 
commercialisation and private for-profit involvement in the health sector in East and 
Southern African countries.’ As indicated by the terms of reference, the focus of the report is 
the formal, for-profit sector. This is because, if unregulated, large-scale commercial 
enterprises have considerable potential to impact negatively on equity and destabilise the 
health system, as shown by the international literature critiquing the commercialisation of 
health care (see, for example, Mackintosh and Kovalev 2006) and the experience of South 
Africa since the 1990s (see, for example, McIntyre 2010). This is not to say that the informal, 
for-profit and non-profit sectors are not also capable of impacting negatively on health 
systems. On the contrary, interventions to improve the quality of care offered by the informal, 
for-profit sector in Sub-Saharan Africa are required urgently, especially in countries where 
the public health system is very weak (see, for example, Goodman, Brieger et al. 2007). 
Research on these sectors is thus certainly necessary but beyond the scope of this report. 
 
As much of the IFC report was also addressed to the formal, for-profit private sector, this 
report uses the IFC’s conceptual framework to structure its analysis. The report first 
summarises the rationale behind the IFC’s recommendations and the opportunities for 
private sector investment that it identified. It then explores whether there are signs of 
increasing private sector activity in the region. The report then goes on to alert regional 
Ministries of Health and external funders to issues for concern based on regional experience 
of private sector activity in the past.  
 
The body of the report identifies recent trends in the private sector in broad terms while the 
Annex provides specific examples of recent private initiatives in the region. The focus is on 
initiatives since 2007 although some data are from slightly before this date, depending on 





This report is based on a rapid desk-based search of the predominantly grey literature on 
for-profit private sector activity in the health sectors of East and Southern Africa. Initially key 
words such as ‘private health sector’ or ‘private hospital’ were entered together with ‘Africa’ 
or individual country names into PUBMED and Google, with a focus on the last five years. 
As initial sources were identified, the search was refined by entering the names of private 




company reports or industry newsletters were also followed up. Given resource constraints, 
only references relating to types of private financing, health care provision, risk-pooling 
arrangements and pharmaceutical manufacture and distribution were pursued. In any case, 
these account for the bulk of private sector investment opportunities (IFC, 2007).  
 
Information on other activities, such as the manufacture and distribution of medical products 
and IT systems, retail activities and health professional education has therefore been 
excluded although they certainly warrant research in their own right. This report is therefore 
only an initial scoping exercise that needs to be followed up by more detailed and systematic 
research. It is not able to provide a comprehensive overview of recent commercial activity in 
the region or the level of investment. As the report relies exclusively on secondary data, and 
much of the data are not from peer-reviewed sources, the reliability of the data may be 
questionable in some cases. However, some data are from reliable sources, in some cases 
it has been possible to triangulate data and, as a whole, the data are able to suggest areas 
for further investigation.  
 
3. The IFC’s case for expanding the private health sector 
 
The IFC report rests its case for the expansion of the private sector in Sub-Saharan Africa 
on the following argument: 
1. Already, 60% of health financing is from private sources. 
2. Also, 50% of health expenditure is spent on private providers. 
3. Rapid economic growth is set to expand the African middle-class, increasing the capacity 
to pay for care and consequently the demand for good quality services. 
4. Demand is also increasing due to new developments in the health sector, such as the 
emergence of generic drugs, low-cost insurance and medical tourism. 
5. The public sector is unable to meet even current demand because of a shortage of 
capital and human resources and problems with efficiency and quality. 
6. External funding is also stagnating. 
7. The private health sector has the wherewithal to address this gap and offers private 
investors good returns on investment, particularly as political stability and good 
governance practices emerge on the continent. 
8. Therefore, both businesses and country health systems can benefit from a stronger 
private sector. 
 
In presenting this argument, the IFC report notes that the private sector is made up of both 
formal and informal components and that each of these consists of for-profit organisations, 
social enterprises (or ‘not-for-profits’) and non-profit organisations. (Social enterprises are 
businesses whose social purpose is central to their operation. Profits are used more to 
further social aims than to maximise shareholders’ returns on investment). It also 
acknowledges that these different components may be driven by different incentives. 
However, the report does not differentiate clearly between different components when 
presenting its analysis of successful private sector case studies. At the same time, many of 
the conclusions, and much of the language of the report, are addressed to the formal, for-
profit private sector, for instance, through frequent references to ‘investment’ and ‘returns on 
investment,’ as well as the very title of the report, The Business of Health in Africa. 
 
 
4. Opportunities for private investment in the health sector 
 
The IFC report identifies the health sector as one of the top-five most promising investment 
areas in Africa, expanding at the rate of the telecoms or infrastructure sectors (Rundell 
2010). According to the IFC, ‘for health care companies looking for markets in which to 




$20 billion in private health care expansion [in Sub-Saharan Africa] represents a significant 
opportunity’ (IFC, 2007:15). About 60% of these expansion opportunities could attract for-
profit investors.  
 
The IFC identifies five sub-components of the health sector that are attractive to private 
investors: 
 health services provision (outpatient and inpatient), representing 50% of current 
investment opportunities; 
 risk-pooling arrangements, representing 13%; 
 life sciences-related activities (pharmaceuticals and medical products), representing 
14%; 
 retail and distribution, representing 14%; and 
 medical and nursing education, representing 9% (IFC, 2007). 
 
These sub-components are described in detail in Table 1 which provides a useful framework 
for understanding investment opportunities in the health sector. Most opportunities are for 
small- and medium-sized enterprises (except for manufacturing of pharmaceuticals and 
medical products which attract large investments). For-profit examples of existing 
enterprises from the East and Southern African region that were quoted in the IFC report are 
included in Table 1. 
 
 







Health services provision 
Small, high-end hospital 
(profits can be 30%) 
‘boutique’ hospital located in urban area, 
providing high quality care and targeting the 
wealthy and expatriates 
Tanzania: Tanzania 
Heart Institute in Dar 
es Salaam 
Network of primary and 
secondary clinics 
integrated set of facilities extending into lower-
density areas, sharing overhead costs, 
management expertise and procurement 
systems; economies of scale allow specialised 
services to be delivered 
Uganda: Clinic Africa 
Hospital offering in-
house insurance 
offers own insurance scheme to families where 
the catchment population is uninsured; requires 





located in high-density area, providing basic 
care and targeting low-income people (patient 
through-put can be up to 100 patients per 
doctor per day); sometimes specialises in one 




fees differentiated by patient income, with 
better hotel services provided to patients 
paying higher fees; quality of care supposedly 
not differentiated by fee level 
Uganda: International 
Hospital in Kampala 
Large diagnostic 
laboratory 
diagnostic laboratory providing diagnostic 
services to geographic area that can be quite 
wide-ranging 
 
Telemedicine doctors in urban area provide advice to clinic 
nurses by phone or internet, particularly in rural 
areas where there is a shortage of doctors 
 
Specialised doctors 
covering network of 
hospitals 
group of specialists travels between facilities 
with equipment to treat pre-booked patient; in 












within general insurance 
health insurance offered by general insurers 
with a fee based on risk profile 
Tanzania: Strategis 





with service providers 
organisation providing insurance coverage 
together with access to selected providers, 
using managed care principles 
model fairly developed 





health insurance sold together with micro-
finance products  
Life-sciences related activities (pharmaceuticals and medical products) 
Generics manufacturing formulation of generic medicines (prescription 
and over-the-counter) 
South Africa: Aspen 






manufacturing of medical supplies (e.g. long-
lasting mosquito nets, medical gauzes, medical 
furniture) 
 
Life sciences innovation 
(South Africa) 
financing innovation and commercialisation of 
local research outputs 
Almost exclusively 




infectious and neglected 
disease research 
financing commercialisation and local 
application of research conducted globally  
 
Retail and distribution 
Pharmacy chains (most 
profitable opportunity 
e.g. 50%) 
consolidation of individual outlets into chains 
that compensate for lower margins (usually as 





shared transport of pharmaceuticals (especially 
over-the-counter medicines) with soft drinks 




integration of different components of the 
supply chain, sometimes paired with 
distributing several different brands 
Sub-Saharan Africa: 
Fuel Africa (part of 
South African Fuel 
Group) 
South Africa: PHD 
Pharmacy accreditation 
programmes for 
informal retail operators 





external funders or 
governments 
private company managing supply chain 
 





Schools for nurses, 













Although the IFC report is not explicit about how private entities could become involved in 
financing the African health sector, the most common likely models are foreign and 
domestic direct investment or the provision of loans (otherwise known as debt financing), 
both directly to local companies or through local banks. Private equity funding could be 
stand-alone or twinned with external or government funding. 
 
Ownership could be entirely private through the creation of new institutions or arise through 
the privatisation of existing public services. Alternatively, private-public partnerships could be 
set up, examples being where private enterprises: undertake specific functions on behalf of 
the public sector through service contracts; manage publicly-owned health facilities through 
management contracts (usually for between two and five years); rent and upgrade existing 
public health facilities through lease contracts; or provide substantial new capital to public 
establishments and use the refurbished facility for a specified time, usually ten years or more 
(a concession contract). 
 
5. Changing private sector investment patterns in East and 
 Southern Africa 
 
This section looks at whether, despite the global economic recession, there are signs that 
the opportunities identified by the IFC have been taken up in recent years, especially since 
2007. The section begins by identifying some new private financing initiatives and then goes 
on to present some examples of new investments in the formal, for-profit health care sector. 
With respect to the latter, and as indicated earlier, resource constraints have meant that this 
report is only able to focus on the components of health care provision, risk pooling and 
pharmaceutical manufacture and distribution.  
 
The Annex provides more details on the initiatives described in this section, as well as some 
other initiatives. This inventory is incomplete because of data limitations and is only a first 
step towards understanding the range of private sector initiatives in the region.  
 
5.1 New private financing initiatives 
New private financing initiatives include: 
 the creation of development funds focused on the private sector; 
 private equity funds; and 
 the provision of debt financing. 
 
In 2005 a fund was established in the Netherlands to bring together development funding 
(from governments and external funders) with funds from the private sector. The Health 
Insurance Fund, which is supported by the Dutch Ministry of Development Cooperation, is 
intended to provide a mixture of public, external and private funding to stimulate private 
health insurance companies, creating a demand for private provision. PharmAccess, a Dutch 
NGO, has been appointed to manage the Fund and is very active in developing models and 
contracts to facilitate private health insurance. The Africa Health Fund was launched in 
2009 by the IFC. It is backed by four investors - the IFC, the African Development Bank, the 
Deutche Investitions- und Entwicklungsgesellschaft (DEG) and the Bill & Melinda Gates 
Foundation. DEG is part of a banking group. It finances investment by private companies in 
developing countries.These have provided ‘seed’ funding to encourage other investors – 
both external funders and private companies - to contribute.  
 
The Fund seeks to invest in private businesses that provide affordable, high-quality health 
care services to low-income populations whilst at the same time providing satisfactory long-




investment was acquiring a stake to the value of US$2.66 million in the Nairobi’s Women’s 
Hospital with the aim of expanding its services in the region. The hospital reportedly provides 
substantial health care to poorer populations. 
 
Private equity funds are reportedly examining the African health care sector as a potential 
source of profit, rather than just an avenue for social responsibility programmes (Mbogo 
2010). Increasing investment from international companies is expected. For example, the 
US-based hedge fund Harbinger Capital Partners has bought a controlling stake in African 
Medical Investments which aims to become a leading operator of high-end hospitals. 
 
The Netherlands-based Investment Fund for Health in Africa was established in 2007 and 
provides private equity to invest in private health providers. It is a private equity fund that 
provides long-term capital to small and medium enterprises. Amongst its shareholders is 
Pfizer. Projects include a pharmaceutical wholesale and distribution company and a private 
health insurance company, Strategis, in Tanzania. In 2010 it purchased a 20% stake in a 
private insurance scheme, AAR East Africa, that is based in Kenya but operates in many 
other countries in the region. 
 
The Medical Credit Fund, which is also co-ordinated by PharmAccess, the Dutch NGO 
coordinating the development fund described above, provides debt financing to private 
providers, primarily in the primary care sector (private GPs and dispensaries). Established in 
2009, the fund provides loans through local banks, as well as technical advice, to private 
primary care facilities and dispensaries in Africa, including Tanzania and Kenya. In return, 
practices are required to upgrade their facilities and services. A seemingly separate 
programme was started in 2007 in Zambia to expand access to finance for the private health 
sector (McKeon and Musona 2009). 
 
5.2 Increasing investment in profitable components of the health sector 
 
Several trends in hospital care are apparent. First, international private investors – such as 
the Indian hospital group Fortis Healthcare and the private equity company African Medical 
Investments which is based in the Isle of Wight - are expressing interest in funding high-end, 
‘boutique’ hospitals that target the high-income, expatriate, diplomatic, NGO and medical 
tourism markets. These hospitals make no pretence at serving lower-income populations. 
Start-up countries include Kenya, Mauritius and Tanzania. Even Mozambique has seen the 
opening of one of these hospitals, despite it being one of the poorest countries in the region. 
African governments are reportedly actively seeking such investments. 
 
Second, some South African private hospital networks seem to be preparing to expand into 
the region. While Medi-Clinic already has a presence in Namibia it appears to be 
concentrating its current expansion in Switzerland and the Gulf States, but Netcare has 
recently embarked on an IFC-brokered public-private partnership at a hospital in Lesotho 
(reportedly as the first step in expanding into other areas of the region) while the IFC has 
bought a stake in Life Healthcare to help it transfer management expertise to other African 
countries. Third, the IFC has become active in promoting private hospitals elsewhere in the 
region. For example, in Uganda it has facilitated a loan to a private hospital owned mainly by 
private specialists working at the hospital. At this hospital, laboratory services are contracted 
to a South-African linked company, Lancet.  
 
In terms of primary care, it was very difficult to find information on individual practitioners. 
However, McKeon and Musona (2009) note that, in Zambia, although the formal private 
sector is small, recent years have witnessed a sudden growth with around 23% of 432 




With regard to risk-pooling arrangements, the heavy reliance of African health systems on 
out-of-pocket payments has long been criticised because this form of financing is the most 
inequitable and exposes households to catastrophic financial risk at the time of illness. In 
recent years private health insurance has been promoted as an alternative, by PharmAcess 
and the IFC in particular, because it encourages prepayment and the pooling of health risks. 
Private health insurance is seen as providing business opportunities to private companies 
administering the insurance scheme as well as stimulating the market for private health care 
providers. Third party payments are also seen as reducing the risks to private providers of 
non-payment of fees by their clients (McKeon and Musona 2009). Collective insurance that 
targets whole communities, rather than individual health insurance, is being promoted. With 
time it is hoped that private health insurers can form the basis for the development of more 
extensive social health insurance. This approach (as opposed to developing social or 
national health insurance) appears to have been driven largely by institutions based in the 
Netherlands where, historically, universal coverage emerged on the basis of this model. It 
appears that early experiments with private health insurance are beginning in Tanzania on 
the back of earlier experience in Namibia and Nigeria. Some funding has been provided by 
the Health Insurance Fund and the process is being overseen by PharmAcess. The local 
implementing partner is the private health insurer Strategis that was registered in 2003 and 
is reportedly growing rapidly. The South African general insurance company, Liberty 
Holdings, is also reportedly set to expand its activities into neighbouring countries. 
 
Pharmaceutical manufacture and distribution is also growing in Africa. Rundell (2010) 
notes that ‘most multinational drug companies are now targeting Africa for their next growth 
phase.’ It is beyond the scope of this report to detail all of these initiatives, most of which 
build on the pre-existing presence of these multinationals. Interestingly though, India and 
China have become prominent exporters of pharmaceuticals to South Africa (Kudlinski 
2009): this probably signals a change in the range of companies present on the continent. It 
is worth singling out the case of the South African company Aspen Pharmacare. Box 1 
shows its rapid growth in the region through diversifying its product range, buying a stake in 
existing regional companies and developing a partnership with GlaxoSmithKline. 
 
Box 1: The regional growth of Aspen Pharmacare 
Aspen was founded in 1997 and enjoyed a 40% per annum growth in its first decade. In 2008, the 
value of its manufacturing facilities – in South Africa, Kenya and Tanzania - was over R1 billion. 
Within South Africa Aspen is the top manufacturer of generics while, worldwide, it is one of the top 20 
generics manufacturers. Initially Aspen was principally associated with the provision of drugs for the 
treatment of chronic diseases, especially HIV and AIDS and TB. Today, however, it supplies branded 
and generic drugs, as well as nutritional and consumer products: this diversification is partly due to 
declining returns it experienced on generics with the entry of Chinese and Indian generics 
manufacturers into the African market. Starting in 2005, the South African Department of Trade and 
Industry has made Aspen a beneficiary of its Strategic Investment Programme, a government policy 
to entice investors into new business concerns – including the pharmaceutical sector - through the 
granting of tax relief in the form of a capital allowance. In 2010 this lowered Aspen’s tax bill by R46 
million. While Aspen’s activities in Sub-Saharan Africa only contributed 9% of group revenue in 2010, 
it is actively seeking to expand its activities in the continent. This expansion appears to be founded on 
two main strategies. First, in 2008 Aspen acquired a 60% interest in the ailing Tanzanian Shelys. 
Second, in 2009 GlaxoSmithKline, which is the world’s second largest seller of prescription drugs, 
acquired 16% of Aspen’s shares, and a non-executive director on its Board. This was in exchange for: 
 giving Aspen the rights to market, sell and distribute GlaxoSmithKline’s pharmaceutical products 
in South Africa for a minimum of 20 years; 
 collaborating with Aspen in the marketing and selling of pharmaceuticals1 to Sub-Saharan Africa 
under the brand ‘The GSK Aspen Healthcare for Africa Collaboration’ (most of the combined 
sales were formerly by GlaxoSmithKline); 
 giving Aspen the rights to eight specialist branded products for worldwide distribution; and 
 giving Aspen GlaxoSmithKline’s manufacturing facility in Germany which produces some of the 
products that have been divested.  




5.3 Overall trends in the region 
Data limitations mean that only tentative conclusions can be drawn from the inventory of new 
private sector initiatives described above and in the Annex. It must be kept in mind that there 
may well be other important initiatives that have not been reported in the press, studied by 
other researchers or identified by this review. Using what information is presently available, 
Table 2 shows, first, that taken together there does seem to be a number of new for-profit 
initiatives in East and Southern Africa. These initiatives span the range of private sector sub-
components that are the focus of this report, although it is least clear what is happening with 
respect to private general practitioners and specialists. Even very poor or recently war-torn 
countries are receiving these investments, some of which are for high-end ‘boutique’ 
hospitals.  
 
New private sector activity seems to be vigorous in some countries in particular, namely 
Kenya, Uganda and Tanzania (see Box 2 for a case study of Kenya). Why this is so, is a 
matter for speculation. Reasons could include the presence of a good skills base, business-
friendly policies and deregulation of the health system (McKeon and Musona 2009; Ruiters 
and Scott 2009). The efforts of international agencies must not be discounted. For example, 
in Zambia, apart from the IFC, the USAID-funded Banking on Health project was active in 
designing a programme to finance and support the sustainable delivery of reproductive 
health and family planning services in the private sector (McKeon and Musona 2009). 
 
Box 2: Private sector expansion in Kenya 
The value of the health services industry in Kenya has risen steadily from Sh33 billion in 2004 to Sh51 
billion in 2008. A recent newspaper report estimated that private equity’s interest in private hospitals 
has more than tripled in the past two years and is expected to peak at no less than Sh1 billion by the 
end of the year. Private equity funds account for Sh500 million in the past two years, a growth from 
zero in 2007. Foreign private enterprises’ interests in Kenya has been rising steadily from five in early 
2000 to an estimated 25 currently.  
 
Thus, for example, in 2008 TBL Mirror Fund BV purchased a significant stake in Meridian Medical 
Clinics that operates medical facilities providing outpatient medical services. This helped the chain 
increase from 3 to 10 private clinics. The TBL Mirror Fund provides venture capital, entrepreneurial 
expertise and access to an international investor network for small and medium Kenyan enterprises. 
The company is based in Nairobi, Kenya. Kenya was one of the first countries that the IFC-World 
Bank Health in Africa initiative chose to work in. In January 2010, Aureos Capital, which manages the 
Africa Health Fund, bought into Nairobi Women’s Hospital for Sh200 million ($2.66 million). Nairobi 
Hospital then bought Masaba Hospital to extend its services: this is now known as The Nairobi 
Women’s Hospital-Adams. The hospital is also looking for private equity funds to boost its expansion 
plan. More than half the services of the hospital are for the poor. An unknown private equity fund is 
also in talks with Karen Hospital in Nairobi to expand its presence in the region. As historically Kenyan 
hospitals have tended to only seek modest returns, the introduction of investors with a profit motive 
may signal price increases. 
 
The few private insurers in existence are serving only the high end of the market. The private health 
insurance sector in Kenya is still relatively small, covering about 2%of the population, mostly high-
income groups working in the formal sector. There is strong interest in developing low-income private 
insurance . However, Kenya is also implementing an NHI fund pilot. Acumen Fund (a non-profit 
venture capital fund that favours social projects) has bought a stake in a new eye hospital and a 
pharmaceutical franchise of low-cost pharmacies. It is also planning to invest in a hospital in 2011. In 
general the pharmaceuticals sector is growing rapidly and was expected to have double-digit growth 
in 2010.  







In addition, the private sector-oriented NGO, PharmAccess, appears to have very wide-
ranging influence in the region. 
 
Another noted trend is that several South African companies are amongst those expanding 
into the rest of the region. South Africa’s regional dominance may be measured in medical 
supplies, equipment and drugs which comprised almost 10% of high technology exports to 
the Southern African Development Community in 2008 with Tanzania, Zimbabwe and 
Mozambique being major recipients (Ruiters and Scott 2009). It seems that recent South 
African investment has been driven by a powerful push-pull combination of saturation of the 
domestic market, relatively high profit margins in regional markets, a relative lack of interest 
by multinationals in competing for markets in the region, the economies of scale presented 
by large South African companies , liberalised conditions for the repatriation of regional 
earnings by South African companies and stronger regulation in South Africa pushing capital 
over the border (Ruiters and Scott 2009 ). Fears in South Africa that the proposed National 
Health Insurance system might curtail opportunities for private providers may also be 
contributing to this trend. 
 
Finally, Ruiters and Scott (2009:2) note that, ‘even if the FDI dries up, internal shifts in the 
health sector within countries, even those not regarded as good investment options, are very 
significant as Zimbabwe and Tanzania show.’  
 
Table 2  overleaf gives examples of recent or planned private sector initiatives in east and 
southern Africa. 
 
6. Issues in private sector expansion  
 
Clearly, backing for an increased role for the private health sector - especially the for-profit 
component - emanates not only from the IFC, but also from other international agencies and 
initiatives such as WHO, USAID, the Global Fund to Fight AIDS, Tuberculosis and Malaria 
and the Bill and Melinda Gates Foundation, as well as development-oriented Western 
governments, such as the United Kingdom and the Netherlands (Ruiters and Scott 2009). In 
addition, a World Bank-IFC report that has just been published has begun to address how 
relationships between governments and the private sector could become more structured 
(World Bank and IFC 2011).  
 
Governments within the East and Southern African region have also begun to seek private 
sector investment more actively. Thus, for example, in 2010 the Zimbabwean government 
launched an appeal for additional funding to the tune of $700 million in order to raise per 
capita spending on health care from $9 to $34. The appeal was backed by WHO, UNICEF 
and the World Bank and included a call for the investment of private funds (Associated Press 
2010). Mauritius is also actively inviting Indian investors to invest further in the country as 
part of its strategy to become the destination of choice for ‘medical tourism’ (Bhuckory 2011).  
 
The South African experience, on the other hand, raises questions about the degree to 
which expansion of the for-profit private sector benefits the general population and the health 
system as a whole. In South Africa, de-regulation in the late 1980s saw the proliferation of 
private health insurers, fragmentation of risk pools, reduced income and health cross-
subsidies, rising costs for health insurance premiums and private health care provision 
(especially by hospitals), declining coverage, increased vertical integration (resulting in 
declining competition) and capturing of public subsidies by the private sector (Doherty and 
McCleod 2003; Doherty and Steinberg 2003; McIntyre 2010). The expansion of the private 
sector, together with higher fees, attracted skilled health professionals away from the public 
sector. At the end of the 1990s, around 75% of specialists, between 50% and 70% of GPs 












































































Angola ()              
Botswana            ()   
DRC ()      ()        
Kenya               
Lesotho            ()   
Madagascar               
Malawi               
Mauritius               
Mozambique ()              
Namibia  ()             
Rwanda ()      ()        
South Africa ()              
Swaziland           ()    
Tanzania ()              
Uganda ()      ()        
Zambia ()          ()    
Zimbabwe           () ()   
*The company has manufacturing plants in these countries but markets to many other countries  
** Not clear where in Africa this company will be expanding  
 Institution is currently in this country 
() Institution is planning to expand to this country 




While in the 2000s there were some hard-won achievements in regulating the practice of 
dispensing doctors, setting single exit prices for pharmaceuticals, controlling dispensing fees 
and re-regulating the medical schemes industry, private providers remain largely 
unregulated in terms of their geographic distribution, fees, reimbursement mechanisms and 
treatment patterns (despite expensive managed care initiatives).  
 
This suggests it would be unwise for governments to encourage the unfettered expansion of 
the private for-profit sector without, first, understanding both the benefits and unintended 
consequences and, second, putting in place appropriate regulation (together with the 
capacity to evaluate and enforce it). This section identifies particular issues for concern, 
drawing on the South African experience but also supplementing it with emerging evidence 
from other countries in the region. 
 
6.1 Limited information on the impact of the for-profit private sector  
 
The IFC report argues that a stronger private sector would offer advantages to the health 
systems of countries. For example, it would introduce new management skills, raise 
standards of care, help to stem the brain drain from Africa by creating pleasant, well-paying 
work opportunities, and develop human resources.  
 
However, the IFC report does not differentiate clearly between the for-profit and non-profit 
private sector when putting forward these arguments. This is problematic, for example, when 
the report argues that the private sector will improve health care coverage, including for low-
income communities, because the models it quotes to substantiate this view tend to veer 
towards the social enterprise - or even non-profit – side of the spectrum. Further, the report 
uses the current size of the private sector as justification for its policy relevance, without 
indicating that the for-profit component is relatively small, serving only a fraction of the 
population that tends to be better-off. 
 
Neither does the report present hard evidence on the impact of the private sector, whether 
for-profit or non-profit. Case studies are presented but the evidence on which they are based 
does not seem to be publicly available. Indeed, internationally there is little systematic and 
comprehensive information on the impact of the private sector on key social objectives 
(including affordability, equity, efficiency, sustainability and quality) or the integrity of the 
health system, a problem aggravated by the fact that for-profit entities are often unwilling to 
disclose information that would allow proper comparisons to be made with public and NGO 
institutions.  
 
Further, governments find it difficult to monitor the for-profit private sector because of 
shortfalls in capacity. Zimbabwe is a case in point as, despite having introduced regulations 
to control the behaviour of medical aid societies, the office in charge of regulation is unable 
to monitor the industry because of a shortage of personnel (Shamu, Loewenson et al. 2010). 
In some cases monitoring does not happen because of a lack of awareness that the 
activities of the private sector are relevant to public health policy, as was the case in South 
Africa during the 1990s (McIntyre 2010).  
 
Evidence on impacts should be a pre-requisite for embarking on reforms the size of that 
envisaged by the IFC report, including a better understanding of the causal pathways 
through which a stronger for-private health sector is supposed to improve the health of a 
country’s population as well as equity. Embarking on a reform without sufficient evidence 
was a feature of another form of commercialisation, the introduction of user fees to 
government facilities in the 1980s, a reform which had negative impacts on access and 





6.2 Weak policy frameworks and limited regulation 
 
Typically governments in the region have not developed coherent, overarching and 
implementable policy frameworks on the for-profit private sector (The World Bank and the 
International Finance Corporation 2011). This applies even to South Africa where there has 
been considerable activity with respect to policy development on sub-components of the 
sector.  
 
Where there is regulation, this is often weak or poorly implemented. This has been the case 
with the medical aid societies in Zimbabwe where medical aid societies have defaulted on 
obligations to provide annual financial reports to the Registrar and hold annual advisory 
council meetings (Shamu, Loewenson et al. 2010; TARSC, SEATINI et al. 2010). Poor 
implementation of regulations is also reportedly a problem in Kenya (Barnes, O’Hanlon et al. 
2010), a country witnessing rapid expansion of the private sector.  
 
A complication in terms of regulation of the private sector is the interface between health 
policy and policy on free enterprise. Whereas Competition Commissions in South Africa and 
Zimbabwe have acted against collusion in the setting of prices by private hospital groups 
and the vertical integration of funders and providers respectively, these actions have been 
based on economic arguments rather than on the welfare of patients. Thus, for example, the 
South African Competition Commission ruled that the association of medical schemes 
should not be allowed to set tariffs for reimbursement of private hospitals and other 
providers, undermining the main tool available to medical schemes (and government) to 
control cost escalation. 
 
It is worrying that the IFC report calls for further de-regulation of the private sector in order to 
improve profitability, even as it acknowledges that regulation is required to protect the quality 
of care.  
 
6.3 Contractual relationships unfavourable to government 
 
When engaging in public-private partnerships, governments often find themselves agreeing 
to terms that are unfavourable in terms of the distribution of risk between the two parties. 
They also find it difficult to impose sanctions when the terms of the contract are violated. 
This has been well-documented in the international literature and was a large problem in 
South Africa in the early 1990s (Monitor Company, Health Partners International et al. 1996).  
 
In the light of this experience it is worrying that such partnerships are being promoted 
actively by the IFC and other international agencies, in the absence of evidence on clear 
mechanisms for ensuring that contracts are fair and binding and that these mechanisms are 
sustainable. Recent projects of the IFC, such as the awarding of a long-term contract to 
Netcare to modernise and run the Queen Elizabeth II Hospital in Lesotho, presumably aim to 
test such mechanisms by providing support to the Lesotho government.  
 
6.4 Subsidising private concerns with public money 
 
The experience of South Africa highlights the extent to which private institutions and health 
insurance beneficiaries have captured public subsidies (see Box 3). In that country, 
government subsidises its own employees to receive private care by an amount greater than 
it spends on public sector dependents. As Marriott (2009:3) notes, this is an example of how 
‘attracting private providers to low-income risky health markets requires significant public 
subsidy.’ It is worrying, therefore, that a new brand of public-partnership is emerging in Africa 




from government and external funder sources. This could lead to governments shouldering 
an unfair degree of risk whilst subsidising profits made by private investors. 
 











 Sources: Monitor Company, Health Partners International et al. 1996; Doherty, Thomas et 
al. 2002; McIntyre, Gilson et al. 2006 
 
 
6.5 Escalating costs 
 
Like any other business sector, the for-profit private health care sector is driven by the need 
to make money out of the services it provides. What seems to be increasing involvement of 
banks, insurance companies and private equity funds in the African private health care 
sector seems to testify to this.  
 
Financial imperatives in the private sector are fundamentally different from the main 
objective driving public health systems and often lead to escalating costs, a perennial 
problem in South Africa. In Zimbabwe, medical aid societies had argued that the integration 
of their funder and provider business arms would allow them to contain costs, but costs have 
risen nonetheless (Shamu, Loewenson et al. 2010). In Kenya, private sector prices have 
been rising by 20% on an annual basis due to the collapse of agreements on pricing 
guidelines (Barnes, O’Hanlon et al. 2010). This has led to the introduction of co-payments 
which were almost unheard of a few years ago. In other countries, another strategy to cope 
with cost escalation is a reduction of benefits. 
 
While the private sector often argues that higher costs relate to better quality of care, new 
technology and ageing populations, there is also evidence that it can be due to business 
tactics such as over-charging, inflated administrative and managed care costs, over-
servicing and risk-rating of premiums. In South Africa, for example, inflated pharmaceutical 
costs due to mark-ups along the supply chain, and especially by private hospitals, have only 
recently been controlled through the introduction of a single exit price. In Kenya, the revenue 
growth in the Nairobi Women’s Hospital is still being driven by pharmaceuticals and is 
expected to reach double-digit growth by 2014 (Mbogo 2010). In fact, the IFC report admits 
that private health facilities often use pharmaceutical sales to cross-subsidise their provision 
costs. 
 
There is also evidence of unethical business practices that take advantage of loopholes in 
the law, such as collusion around prices, stripping of health insurance scheme assets and 
tax evasion. In Zimbabwe, for example, medical aid societies are tax exempt because of 
their non-profit status, despite the fact that they also own non-core businesses that are 
profit-making (Shamu, Loewenson et al. 2010). In South Africa a special tax dispensation 
has benefited large, publicly listed pharmaceutical companies so that, perversely, they face 
 Almost 10% of the government hospital budget was on service contracts with the private 
sector. These contracts were often on terms that were not favourable to government. 
 The same applied to arrangements with ‘district surgeons,’ private GPs contracted to provide 
private health care to the poor on a fee-for-service basis. 
 Private patients using public facilities were under-charged. 
 Employers were given tax relief for contributing to their employees’ medical schemes. In 2005, 
the value of this tax subsidy was equivalent to 20% of the public sector health budget. 
 Government paid high premiums for its civil servants who belonged to medical schemes. In 





lower tax rates than small businesses even though they support capital-intensive rather than 
labour-intensive manufacturing (Kudlinski 2009; Redfern 2010). 
 
What is more, there is very little information on the quality of care (as opposed to hotel 
services) provided by private providers and whether this represents value for money. Almost 
the only failing of the private sector that the IFC identifies is problems with quality of care. 
 
6.6 Growing monopolies and verticalisation 
 
It has long been acknowledged that the health care market is distorted because of 
information asymmetry, making it susceptible to supplier-induced demand. In settings where 
regulation is weak, there is also vertical integration (where different companies in the supply 
chain are owned by the same institution), concentration (where competitors are bought out) 
and collusion (where competitors agree to charge similar prices). This is clear from the 
South African experience (see Box 4) but also, for example, in Zimbabwe where medical aid 
societies have purchased hospitals, clinics, laboratories, pharmacies, dental services, 
rehabilitation services, optometry services, imaging services and emergency transport 
(Shamu, Loewenson et al. 2010; TARSC, SEATINI et al. 2010). In Zimbabwe, beneficiaries 
are often required to use providers belonging to the medical aid society stable. 
  
Box 4: Examples of vertical integration in the South African for-profit private sector 
 Two of the largest private hospital groups (Netcare and Medi-Clinic) each own the two largest 
private emergency response groups (Netcare 911 and ER24 respectively)  
 Private health care providers (doctor groupings and private hospitals) and organisations with 
interests in pharmaceutical and medical equipment manufacturers are investing in medical 
scheme administrators (particularly via Lethimvula) 
 One of the largest private hospital groups (Medi-Clinic) runs the largest private health professional 
employment agency.  
Source: McIntyre 2010 
6.7 Entry of foreign countries into the domestic market 
The South African private health care sector is very powerful and showing signs of 
expanding into the rest of the region. In fact, of the ten-member group of technical advisors 
that advised the IFC in the compilation of its report, three were senior executives from major 
South African companies (Netcare, Discovery Health and Aspen Pharmacare). Expansion is 
happening through Aspen Pharmacare – which, for example, has recently purchased a 60% 
share of the Tanzania pharmaceutical company Shelys Africa - and through other entities 
such as private hospital groups and laboratory services. Although indigenous companies 
may be more attractive options for African governments than foreign companies, it does not 
follow that they will necessarily introduce lower prices, judging from the South African 
experience.  
 
Regional domination by South African companies is not the only threat, however: institutions 
from China, India, Europe and the USA are all showing interest. While more companies 
could lead to greater competition, as has already occurred with respect to the price of 
generics, alliances between different companies (such as that between Apsen Pharacare 
and SmithGlaxoKline) could reduce the effects of competition.  
 
It is not clear, therefore, whether East and Southern African countries will benefit financially 
from new companies expanding into the region, at least to the extent intended by economic 
growth strategies. In addition, it is possible that some public-private partnerships (or large-
scale donations such as those made by some pharmaceutical companies) which are entered 
into on terms favourable to governments, might be a strategy for spring-boarding companies 





6.8 The erosion of the public sector 
 
A strong private sector can permanently undermine efforts to build a strong public sector 
through siphoning off skilled personnel, fragmenting the risk pool (consequently limiting 
opportunities for cross-subsidisation) and building power blocs resistant to regulation. It is 
difficult to reverse private sector expansion once it has begun, or control the behaviour of 
private sector stakeholders, because of the powerful business interests at stake and the 
weak capacity of governments.  
 
For example, risk pool fragmentation is a current feature of the Zimbabwean situation 
following the expansion of medical aid societies (Shamu, Loewenson et al. 2010). It is 
worrying, therefore, that Dutch institutions such as PharmAccess and the Health Insurance 
Fund  are actively promoting private health insurance as a strategy for extending coverage 
based on prepayment. While this model may have worked in several European countries, it 
does not follow that the equivalent preconditions exist in the region (such as strong 
governance, adequate numbers of skilled health personnel and populations that are able to 
afford premiums). 
 
There is an argument that the private sector, whilst it might drain skilled staff from the public 
sector, at least will help to stem the brain drain overseas. This might be so but it does not 
necessarily follow that these staff are used to help meet the country’s health care priorities. 
On the contrary, there is increasing evidence that the for-profit private sector largely serves 
the small, wealthy sector of society. Almost all of the regional examples quoted in this report 
are urban initiatives. As Marriott (2009) notes, data from 44 middle- and low-income 
countries show increasing exclusion of the poor, and most especially women, from care with 
increasing participation of the private sector in primary health care. What is more, the for-
profit sector focuses almost exclusively on curative care and does not participate in wider 
public health initiatives.  
 
 
7. Conclusion and recommendations 
 
Although there are many limitations to the data gathered in this report, it appears that there 
may have been a discernible change in the pattern, if not the level, of private sector 
investment in East and Southern Africa since 2007. Given the concerns listed above, 
Ministries of Health should remain cautious about fostering the expansion of the for-profit 
private sector and entering into public-private partnerships without careful prior planning. 
Government policy needs to protect the integrity of the health system against financial and 
other incentives that distort service provision, raise prices and impact negatively on equitable 
access to good health care. As noted by a recent Oxfam report, ‘there is considerable and 
increasing evidence that there are serious failings inherent in private provision which make it 
a very risky and costly path to take’ (Marriott 2009: p2).  
 
This means that Ministries need to: 
 highlight for their own governments not only the advantages but also the potential pitfalls 
of encouraging for-profit private sector provision as part of their economic growth 
policies; 
 assess the opportunity costs of supporting the for-private health sector as opposed to 
developing the public health system; 
 require health impact assessments before encouraging for-profit private sector activities, 
especially those subsidised by government or external funds (focusing on the impact on 





 evaluate the impact of existing private sector activities on core social objectives and set 
monitoring systems in place; 
 develop comprehensive policies on the private sector as well as a robust regulatory 
framework; 
 develop the capacity of government to monitor private sector activity, develop policies 
and regulations, and enforce sanctions; and 
 act firmly against the development of monopolies and unethical business practices; and 
 prioritise activities that improve coverage in rural areas and low-income populations.  
 
For Ministries to gain support for this approach to the for-profit private sector, especially 
amongst external funders, it is essential that they be able to provide a viable and good 
quality alternative to for-profit private care. This requires injecting adequate resources into 
the public health system as well as developing strong management systems. 
 
Further research is also required to document the array of formal, for-profit private activities 
in the health systems of the region, understand the impact of these activities better and 
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Annex 1: Examples of private sector companies and initiatives 
expanding into the health sector in East and Southern Africa 
 
The information provided in this section is as sourced in the public domain literature 
indicated on the date indicated. It may thus not represent the situation as of current date. 
The author presents what was found in the literature and attributes source, acknowledging 
that in a rapidly changing situation there may be differences to the current situation.  
 
The Africa Health Fund (also known as the Health in Africa Fund) 
Sources: Minney 2010; The Nairobi Women’s Hospital 2010; African Development Bank Group 
2011 
 
The Africa Health Fund (also known as the Health in Africa Fund) was launched in 2009, forming 
part of the IFC-World Bank Health in Africa Initiative. It is a new private equity fund that seeks to 
invest in a wide range of sustainable private businesses that provide affordable, high-quality 
health care services to low-income populations whilst at the same time providing satisfactory 
long-term returns to investors. It also aims to provide innovative advisory services and 
technology.  
 
The Fund is backed by four investors who have provided ‘seed’ funding to encourage other 
investors – both external funders and private companies - to contribute to a final target of 
US$100 million by the end of 2010. The original investors have jointly invested $57 million: the 
International Finance Corporation (IFC) ($20 million), the African Development Bank ($20 
million), DEG ($10 million) and the Bill & Melinda Gates Foundation ($7 million).  
The Fund plans to make about 30 investments, ranging from $250,000 to $5 million and it hopes 
to exit from investments within five to seven years. Although viable investment opportunities from 
all parts of Africa will be considered, priority countries in the region include Kenya, Tanzania, and 
Uganda. Angola, Democratic Republic of Congo, Mozambique, Rwanda, South Africa, and 
Zambia are expected to follow.  
 
In 2010 the Fund’s first investment was acquiring a stake to the value of US$2.66 million in the 
Nairobi’s Women’s Hospital. This private hospital provides outpatient and inpatient care to 
women and children and includes a Gender Violence Recovery Centre that is an unusual 
resource in East Africa. A proportion of the sum invested in the hospital will be used to help fund 
a management buy-out, with the balance going to the expansion of facilities such as clinics, 
beds, ambulances and operating theatres in the country and possibly further afield in the East 
Africa Region. It is not clear how investment in this hospital achieves the Fund’s aim of 
enhancing access by the poor to improved health care. 
 
The Africa Health Fund is managed by British private equity fund Aureos Capital. 
  
African Medical Investments and VIP Healthcare Solutions 
Sources: African Medical Investments 2010; Feller 2010; Medical Tourism News 2010; Shazar 
2010; West 2010 
 
African Medical Investments PLC was incorporated as an Isle of Man registered company in 
2008 and shortly thereafter began trading on AIM, the London Stock Exchange’s international 
market for smaller, growing companies. It is run by people who are also involved in companies 
investing in other sectors in Africa. 
 
African Medical Investments was formed to invest in, or acquire, businesses that operate in the 




that target the African middle class and the expatriate, NGO, diplomatic and tourist markets. Its 
health facilities are managed and operated by AMI’s wholly owned subsidiary, VIP Healthcare 
Solutions, which it acquired in 2008. 
The company started in 2009 with its first 30-bed hospital in Dar es Salaam (Tanzania), followed 
by a 30-bed hospital in Maputo (Mozambique). Both include trauma centres and well-woman 
clinics. A trauma centre in Harare that used to belong to VIP Healthcare Solutions is being 
upgraded during 2010. A facility is also being upgraded for a well-man and well-woman clinic in 
Nairobi (Kenya).  
 
African Medical Investments aims to rapidly roll out its facilities, with a target of 10 facilities by 
2012 and 15 by 2015. African governments are reportedly contacting the company to bring 
facilities to their countries and the company is said to be considering facilities in Lubumbashi 
(DRC), Accra (Ghana), Kigali (Rwanda), Kampala (Uganda) and the DRC’s Katanga province. 
However, it may be withdrawing from the airport medical and travel vaccination centres that VIP 
Healthcare Solutions used to run in Johannesburg and Cape Town, South Africa, at the time it 
was purchased by African Medical Investments (this may be because these facilities do not 
conform to the company’s niche market as well as because financial irregularities have surfaced 
at these facilities). It is not clear what is happening to a similar clinic run by VIP Healthcare 
Solutions at Nairobi’s Kilimanjaro airport. 
 
Aspen Pharmacare Holdings Ltd. (‘Aspen’) 
Sources: International Finance Corporation 2007; Aspen Holdings 2008; Woolman and Sprague 
2008; GlaxoSmithKline 2009; SAinfo reporter 2009; Aspen Holdings 2010; Aspen Holdings 2010; 
Beukes 2010; Redfern 2010  
 
Aspen is a South African pharmaceutical company that was founded in 1997. Within a couple of 
years it had taken over SA Druggists and expanded its manufacturing capacity considerably. In 
2008, the value of its manufacturing facilities was over R1 billion. Aspen’s rapid growth, which in 
its first decade was around 40% per annum, was due not only to innovative business decisions 
but also to a new political and economic climate in South Africa at the end of the 1990s: following 
protracted legal battles, multi-national pharmaceutical companies had agreed to issue ‘voluntary 
licenses’ to South African companies to manufacture generic equivalents of branded HIV and 
AIDS drugs still under patent, while the government had undertaken to roll out anti-retroviral 
therapy to its population. What is more, the South African Department of Trade and Industry 
made Aspen a beneficiary of its Strategic Investment Programme, a government policy to entice 
investors into new business concerns – including the pharmaceutical sector - through the 
granting of tax relief (see Box 5). 
 
Box 5: The South African government provides Aspen with tax relief 
In the 1990s the South African pharmaceutical sector went into decline as multi-national corporations 
disinvested and 37 manufacturing plants closed over a period of fifteen years. Some of the reasons 
for this were the availability of generic medicines, growing pressure on pharmaceutical prices, 
regulatory obstacles and weak incentives for investment. Domestic investment in pharmaceuticals 
was low and there was a growing technology gap between South Africa and high-income countries. 
South Africa increasingly relied on imports and became increasingly vulnerable to interrupted 
supplies, especially of active pharmaceutical ingredients which it had no capacity to produce 
internally. 
 
Government responded by identifying the pharmaceutical industry, and especially the manufacture of 
generics, as a ‘lead sector’ under its first Strategic Investement Programme to boost manufacturing 
and other sectors. This Programme ran from 2002-2006 and sought to attract investors, increase 
competitiveness and create employment by providing tax relief to companies investing at least R50 
million in innovative, wealth-creating projects. The tax benefit was an initial capital allowance of 50% 
or 100%, depending on the qualifying score of the investment. This allowance was additional to the 
normal capital depreciation allowance: together, these allowances substantially lowered the marginal 




paper forward year on year, some were able to operated in a virtually tax-free environment for many 
years. 
 
Out of the Strategic Investment Programme’s total of R10 billion in tax allowances, R813 million was 
allocated to pharmaceutical projects, specifically to promote generics for the treatment of HIV/AIDS 
and TB and leverage the opportunities for local companies provided by state tenders for ARVs. One 
of the beneficiaries was Aspen which received two tax allowances for different projects, one to the 
value of R110 million (for a projected capital of R170 million in 2003 that was escalated to R 360 m in 
2008), the other to the value of R170 million (for a projected capital cost of R 170 million in 2005 that 
was escalated to R 370 million in 2008) (note: the source for these figures was not entirely clear). In 
2010 this lowered Aspen’s tax charge by R46 million. 
 
Initially Aspen was principally associated with the provision of drugs for the treatment of chronic 
diseases, especially HIV and AIDS and TB. Today, however, it supplies branded and generic 
drugs, as well as nutritional and consumer products.  
 
Aspen markets to roughly 100 countries worldwide (including Latin America, Asia-Pacific and 
Australia). It is Africa’s largest pharmaceutical manufacturer, is able to meet stringent quality 
standards and has the capacity to manufacture some active pharmaceutical ingredients, both in 
South Africa and India. Aspen has four manufacturing sites in South Africa (Cape Town, East 
London, Johannesburg and Port Elizabeth) and one site in each of Kenya (Nairobi) and Tanzania 
(Dar es Salaam). Within South Africa Aspen is the top manufacturer of generics while, worldwide, 
it is one of the top 20 generics manufacturers.  
 
Aspen is one of the top 40 companies listed on the Johannesburg Stock Exchange. In 2010 the 
revenue generated from Aspen’s continuing operations was R10,1 billion, and its operating profit 
R2,6 billion, in both cases an increase of 20% over the previous year. Within South Africa, one in 
four script items dispensed in South Africa is for an Aspen product, the most for any company. 
Aspen accounts for almost 17% of sales in the private sector over the last year: its share of 
private sector sales appears to be growing rapidly (at 13%, compared to 3% total market growth). 
With respect to the public sector, Aspen has just been awarded around 40% of the government 
tender for anti-retrovirals. The value of the tender is estimated to be R3.6 billion over the next two 
years, starting at the beginning of 2011.  
 
While Aspen’s activities in Sub-Saharan Africa only contributed 9% of group revenue, Aspen is 
actively seeking to expand its activities in the continent to become the leading provider of 
affordable medicines. This expansion appears to be founded on two main strategies. First, in 
2008 Aspen acquired a 60% interest in the ailing Tanzanian Shelys Group which has operations 
in Kenya and Tanzania. The deal has led to technology transfer, improved efficiency and quality, 
and the addition of Aspen brands to Shelys which is now planning to start ARV production (see 
Shelys Africa case study, Annex B). Shelys exports to Burundi, the DRC, Madagascar, 
Mozambique, Mauritius, Malawi, Uganda and Zambia, providing Aspen with a well-established 
East African distribution platform and a portfolio of well-recognised brands.  
 
Second, in 2009 GlaxoSmithKline, which is the world’s second largest seller of prescription 
drugs, acquired 16% of Aspen’s shares, and a non-executive director on its Board. This was in 
exchange for: 
 giving Aspen the rights to market, sell and distribute GlaxoSmithKline’s pharmaceutical 
products in South Africa for a minimum of twenty years; 
 collaborating with Aspen in the marketing and selling of pharmaceuticals to Sub-Saharan 
Africa under the brand ‘The GSK Aspen Healthcare for Africa Collaboration’ (most of the 
combined sales were formerly by GlaxoSmithKline); 
 giving Aspen the rights to eight specialist branded products for worldwide distribution; and 
 giving Aspen GlaxoSmithKline’s manufacturing facility in Germany which produces some of 





These transactions, which in 2009 had an estimated value of R3.5bn, addressed the 
complementary needs of the two partners. Aspen benefited by making use of GlaxoSmithKline’s 
300 sales representatives in Sub-Saharan Africa and using its brand credibility to market its own 
products. The arrangements also strengthened its manufacturing capabilities, portfolio of 
products and access to international markets. GlaxoSmithKline benefited from Aspen’s strong 
delivery track record to grow its sales to emerging markets, one prong of a three-pronged 
strategy to deal with current business challenges faced by the global pharmaceutical industry. It 
also allowed it to streamline its operations, reduce manufacturing sites and divest itself of low 
priority brands.  
 
For Aspen, growing its business in Sub-Saharan Africa is not without challenges, however. In 
recent years it has faced mounting pressure from other generic manufacturers, especially from 
Asia, who were encouraged to enter the East African market by the dropping of a 10% import 
duty on pharmaceutical products. Unable to lower its own prices in response because of 
contractual arrangements made under voluntary supply agreements, and despite marketing its 
own generic anti-retroviral products and acquiring voluntary licensing agreements, it still has had 
to diversify into other medicines to remain competitive. This is demonstrated by the GSK Aspen 
Healthcare for Africa Collaboration as well as a shift towards branded goods, over-the-counter 
medicines and distribution through supermarkets as has been done, for example, by Shelys. 
Increasing exports into other Eastern and Southern African countries has been another strategy 
adopted by Shelys, along with expanding its business into Australia, the United Kingdom and the 
United States. 
 
Aureos Capital Ltd 
Sources: Frontier Finance 2009; Ruiters and Scott 2009; Aureos Capital 2011; International 
Finance Corporation Unknown 
 
Aureos Capital Ltd was established in July 2001 as a joint venture between CDC Group PLC, the 
UK government’s development finance institution and Norfund, the Norwegian Investment Fund 
for Developing Countries. It is a private equity fund management company with one of the 
longest track records of this sort in Africa. It specialises in providing capital to small- and 
medium-sized companies to allow expansion or buy-out and has over $1 billion under 
management. Aureos has a global presence but it also has regional offices in Kenya, Tanzania, 
Zambia, South Africa and Mauritius. 
 
In 2007 Aureos did an analysis of health care provision in East Africa, including indentifying the 
reasons for health system failure. The study found that the health care sector is undercapitalized 
and suffers from inefficient management, including severe market fragmentation, inadequate 
distribution channels, high manufacturing costs, price distortions, ineffective supply chains, an 
absence of economies of scale, low productivity and an over-dependence on international health 
providers. Aureos seeks to provide financing opportunities for small and medium enterprises to 
address these problems. Aureos is credited with introducing Aspen Pharmacare to Shelys. 
Aureos has been appointed to deploy the Africa Health Fund with a focus on developing 
innovative partnerships with public and private organisations, particularly with respect to 
healthcare financing, medical manufacturing, healthcare training, telemedicine and 
pharmaceutical manufacturing.  
 
Fortis Healthcare Ltd 
Source: Bissoonauth and Martial 2009; Insurance News 2010 
 
Fortis is an Indian private hospital group that was founded in 1996. It established its first hospital 
in 2001 and now owns a network of around 28 hospitals. It is headquartered in New Delhi.  
In 2009 Fortis acquired a private hospital in Mauritius that was formally known as Clinique Darné. 
Fortis is expanding the hospital as well as introducing super-specialties. In this, Forts is aiming at 




Harbinger Capital Partners  
Sources: African Medical Investments 2010; Shazar 2010 
 
African Medical Investment’s strategy to develop into a leading operator of private hospitals in 
Africa is facilitated by a $47 million or more investment in the company by the US-based hedge 
fund Harbinger Capital Partners. Harbinger now has a controlling stake in the company with 
around 54% of the shares. Harbinger has recently begun to invest in Africa as part of a new 
strategy to tap emerging markets. Its involvement in the private health sector possibly arises 
through its investment in a mining company which is run by the some of the same individuals 
running African Medical Investments. 
 
The Health Insurance Fund  
Sources: Health Insurance Fund 2010; Pharmaccess Foundation 2011 
 
The Health Insurance Fund is an independent Dutch foundation that was initiated in 2005. It grew 
out of collaboration between a number of major companies (Heineken, Celtel, Unilever and Shell) 
that had become interested in health care development in Africa, initially through their 
involvement in workplace-based HIV/AIDS programmes. The Fund is registered in Amsterdam, 
The Netherlands. The initiative is supported by the Dutch Ministry of Development Cooperation 
with a subsidy of 100 million Euros for six years. Investments and technical support have also 
been received from a number of Dutch insurance companies and the Dutch multinationals that 
were involved in the initiative from the start. In 2008 the World Bank joined the Fund as an 
external funder. PharmAccess has been appointed as the main implementing partner of the 
Fund.  
 
The Fund seeks to introduce collective private health insurance for low-income groups so that 
they may reap the benefits of prepaid financing and risk pooling. The intention is for external 
funders to subsidise premiums for low-income groups, although members will be expected to 
make a co-payment. The insurance schemes will cover basic health care services, including 
treatment of HIV/AIDS, tuberculosis and malaria. Quality will be enforced through performance-
based payments to a network of providers who may also receive grants to upgrade their 
operations. It is intended that this initiative will generate an increasing demand for health 
insurance and have the potential to evolve into social health insurance.  
 
This approach was based on PharmAccess’s experience with a project it initiated in Namiba (the 
Okambilimbili Project) between 2004 and 2009. Here, public funds subsidised insurance 
coverage for health care (including HIV/AIDS) in low-income communities and uninsured 
individuals in the formal sector for currently uninsured individuals. The project led to the 
introduction of new health insurance products for low-income Namibians and the creation of a 
Risk Equalisation Fund for HIV/AIDS, reportedly the first in Africa. On the back of this 
experience, in 2007 the Health Insurance Fund launched its first insurance scheme - the 
‘Community Health Plan’ - in Nigeria, targeting market women in Lagos and a farming community 
in Kwara State. In 2008 the governor of Kwara State agreed to co-fund an insurance programme 
in the Afon district.  
 
Other schemes are being prepared in other East and Southern African countries, starting in 2010 
with Tanzania. Here, two target groups were selected to participate in the scheme: members of a 
micro-credit NGO called Pride and their families (around 12,000 people) and coffee farmers and 
their families organised in cooperatives. The local implementing partner in Tanzania for 
PharmAccess is the private health insurer Strategis. 
 
The International Finance Corporation (IFC) and the IFC-World Bank Health in 
Africa Initiative 





The IFC-World Bank Health in Africa Initiative seeks to implement some of the recommendations 
arising from the IFC’s report, The Business of Health in Africa. It is interested in fostering the 
following types of activities: 
 health service delivery (e.g. clinics, hospitals, laboratories);  
 risk pooling and financing vehicles (e.g. insurance companies, health management 
organisations);  
 pharmaceutical and medical-related manufacturing companies; 
 distribution and retail organisations (e.g. pharmaceutical chains, logistics companies);  
 medical education providers; and  
 ancillary businesses (e.g. waste management, IT providers). 
 
As part of improving the operating environment for companies, the Initiative seeks to improve 
access to finance. To this end, the Initiative has established a private equity fund (The Africa 
Health Fund) and begun to partner with African commercial banks in Africa to increase the 
availability of debt finance. The Initiative intends to mobilise up to $1 billion in advisory services 
and funds to create public-private partnerships that result in health services for underserved and 
low-income people. The initiative has engaged in a major campaign to convince governments, 
external funders and potential investors of the value of such an initiative. 
 
With respect to the ESA region, and apart from its activities through the Africa Health Fund, the 
IFC has entered into a strategic partnership with Life Healthcare, the second-biggest private 
hospital chain in South Africa. IFC has invested $93.1 million (essentially a 5% stake) to help the 
company invest in and transfer world-class hospital management expertise to other African 
countries and emerging markets in India and Turkey. IFC will jointly finance a subsidiary 
company to support Lifecare’s expansion and will consequently also be investing in other 
countries in the region.  
 
In Uganda, the IFC has made a $3 million loan to Nakasero Hospital in Kampala. This load will 
supposedly help expand health services in the country’s lower-income and under-served areas, 
raise standards, and create jobs for medical professionals. The hospital is a private hospital 
established in 2009 and owned by Ugandan shareholders, most of whom are medical specialists 
practicing at the hospital. Laboratory services are outsourced to Lancet Laboratories Uganda 
Limited which is a joint venture with Lancet Laboratories of South Africa who own 80%. 
The role of the IFC in these deals is partly to provide a ‘stamp of approval’ to projects, 
encouraging private sector partners to provide co-funding. 
 
Investment Fund for Health in Africa 
Sources: Esper 2010; International Finance Corporation 2010; Investment Fund for Health in 
Africa 2010; Investment Fund for Health in Africa 2011 
 
The Investment Fund for Health in Africa (not to be confused with the Health in Africa Fund or the 
Health Insurance Fund) is a Dutch private equity fund that was established in 2007 by the 
PharmAccess Foundation. The PharmAccess Foundation terms it ‘a commercial fund for social 
private equity in the African health sector.’ The Fund is based in the Netherlands but is also 
setting up an investment Fund in Mauritius to facilitate its investments. The Fund hopes to 
provide long-term capital – ranging from EUR 500,000 up to 15% of the Fund’s total 
commitments - to 15-25 small to medium-sized private health care companies working in Africa 
and is managed by African Health Systems Management, a Dutch Company. Many of the team 
managing the Fund formerly worked for PharmAccess  
 
The Fund has investments of EUR 50 million. The existing shareholders of the Fund are FMO, 
Goldman Sachs, Social Investor Foundation for Africa which includes ACHMEA, AEGON, 
Heineken, Shell, SNS-REAAL and Unilever), APG (a Dutch pension asset manager), the African 
Health System Management Company, the African Development Bank, Pfizer (the first 




not to exceed 19.9% of the total capitalisation of the Fund, and also advise the Fund on best 
practice.The Fund argues that investing in private health care companies will increase access to 
quality health care which in turn will lead to increased employment opportunities for healthcare 
professionals in Africa. 
 
The Fund’s first investment was in Hygiea, a Health Maintenance Organisation in Nigeria that 
implements the Health Insurance Fund. In the ESA region, the Fund’s investments include 
Pyramid Pharma in Tanzania which is a pharmaceutical wholesale and distribution company, and 
Strategis Insurance Limited Tanzania. In 2010 it also bought a 20% stake in AAR East Africa, a 
medical insurance provider based in Nairobi but operating in several countries in the region (i.e. 
Kenya, Uganda, Tanzania, Rwanda). The Fund eventually hopes to own 60% of the company 
which is implementing a low-income health insurance project in the Rift Valley together with the 
PharmAccess Foundation. 
 
Liberty Holdings  
Source: Insurance News 2010 
 
Liberty Holdings, a general insurance company, plans to sign up 1.5 million customers over the 
next three years as it expands health insurance products into Africa, specifically Botswana, 
Lesotho, and Zimbabwe. 
 
Lifecare 
Source: Insurance News 2010 
 
The IFC has entered into a strategic partnership with Life Healthcare, the second-biggest private 
hospital chain in South Africa. IFC has invested $93.1 million (essentially a 5% stake) to help the 
company invest in and transfer world-class hospital management expertise to other African 
countries and emerging markets in India and Turkey. IFC will jointly finance a subsidiary 
company to support Lifecare’s expansion and will consequently also be investing in other 
countries in the region. 
 
Medical aid societies in Zimbabwe 
Extracted from: Shamu, Loewenson et al 2010: 2-3 
 
‘Medical aid societies (MAS) in Zimbabwe cover a tenth of the population, and about 80% of 
income to private health care providers in Zimbabwe comes from MAS. They contribute more 
than 20% of the country’s total health expenditure … 
 
In Zimbabwe, medical aid schemes are voluntary. They deal directly with employers and 
consumers, avoiding broker costs, but also limiting employee discretion in the choice of society 
and inhibiting competition in the industry. Benefit packages are clearly specified, but are 
segmented, and lack cross-subsidies between different levels of cover, and different income 
groups of beneficiaries. MAS have encouraged growth of private hospital services in urban rather 
than rural areas, in order to lower administration costs and coverage is higher for the employed 
and wealthier groups, and lower in women, in rural areas and less wealthy people. Members of 
societies were found to be relatively loyal, remaining with their first medical aid society and only 
migrating on change of employment. While managed care systems claim to make it easier and 
less costly to access medicines, this was not found in this survey. Beneficiaries lacked 
information on benefit package options, and there was evidence of restrictive practice and 
benefits shortfall. 
 
The economic liberalisation of the 1990s provided the impetus for greater investment in MAS and 
medical insurance through Greenfield investments, acquisitions and expansions. MAS 




related industries, to manage the costs of doctors, specialists and pharmacists. While 
contributions were used to finance this, other capital flows came from investors from South 
Africa, insurance companies, medical practitioners and banks. Despite societies aiming to use 
these acquisitions as a means to reduce co-payments, clients were found in this survey to be 
making a significant share of payments, including for drugs and consultation fees. Few 
beneficiary plans gave full reimbursement for services provided outside their managed care 
plans, and most clients reported needing to get approval from their MAS to use service providers 
outside those owned by the society. These changes were found to have led to a high degree of 
vertical integration between funders and different providers. This is of concern as it is associated 
with monopolies across all spheres of a sector, limiting patient choice, prescribing practices and 
use of laboratory services being driven by cost more than health need, and limits to people’s 
ability to negotiate their interests with providers. This situation and concerns of the Competition 
and Tariff Commission in part contributed to the passing and of the Medical Aid Societies 
Statutory Instrument 330 of 2000 regulating vertical integration. However regulatory oversight 
itself was found to have been constrained by shortages of personnel in a centralised system, 
ambiguities in the law, lack of information reporting from and monitoring of MAS, lack of 
consumer awareness and lack of advocacy of beneficiary interests by members. 
The societies have taken advantage of these shortfalls and ambiguities to consolidate their 
ownership across the sector and, for some, to default on obligations to provide annual financial 
reports to the Registrar or hold annual advisory council meetings. The Ministry of Health and 
Child Welfare has limited personnel capacity to regulate and monitor MAS, does not have an 
updated database on key features of MAS and does not retain the fees collected from MAS as it 
is not a statutory body. The Ministry of Finance also has obligations to monitor MAS as financial 
institutions. With their non-profit, non-tax status, their investments in non-core ‘for profit’ areas 
now raises new scrutiny on the use of their funds, with potential tax implications on profits 
earned. 
 
The paper made proposals of measures to improve functioning and equity in the sector and to 
address the current exposure of beneficiaries, including: 
 Strengthening the regulatory environment to address legal ambiguities on investment of the 
industry’s ‘surplus’ funds, to ensure the multiple relevant laws from finance and health are 
known and applied by MAS/ insurance providers, and to fairly and firmly enforce the law. 
 Ensuring timely scheme reporting as required by law and maintenance of a database with 
basic information on schemes. 
 Ensuring registration of all schemes, avoiding increasing segmentation of the sector into 
small fragmented risk pools from individual schemes and encouraging (for example through 
enforcement of regulation on registration and liquidity requirements), mergers into larger and 
more viable risk pools. 
 Introducing regulatory and scheme policy measures to require and implement cross-
subsidies necessary for equity and ensuring benefits packages cover personal care and 
personal prevention services. 
 Taking up the shortfalls in coverage of medicines on existing plans. 
 Checking the degree of vertical integration in each scheme and unbundling any monopolies 
across the sector that are limiting patient choice (e.g. paying only for selected linked 
services). 
 Improving the outreach of consumer information on schemes, benefits packages and 
consumer rights to members and organisations servicing members (e.g. the labour 
movement and employer organisations).’ 
 
The Medical Credit Fund 
Sources: Pharmaccess Foundation 2011; Medical Credit Fund Unknown 
 
The Medical Credit Fund was established in 2009 and is the first fund in the world to provide a 
combination of credit and technical advice to private primary care facilities and dispensaries in 
Africa. The rationale behind the Fund is that these providers typically find it difficult to access 




shortfalls in the provision of health care. The Fund provides loans which are administered by 
local banks at rates that are more affordable than ordinary loan facilities, in return for upgrading 
their medical practices. The Fund is managed by PharmAccess. Within the ESA region, the Fund 




Source: Insurance News 2010 
 
Medi-Clinic, the third major private hospital group in South Africa, has operations in Namibia. 
Currently it appears to be seeking to expand into Switzerland and the Gulf States, rather than 
elsewhere in ESA. 
 
Netcare 
Source: Insurance News 2010 
 
Netcare Holdings is the largest private hospital group in South Africa. It also has operations in 
Britain through its stake in General Healthcare Group.  
Netcare Holdings entered into a public-private partnership with the Lesotho government and the 
Development Bank of Southern Africa in 2010. This partnership will replace the ageing Queen 
Elizabeth II Hospital in Maseru. The new hospital will be a national referral hospital and have 
around 425 beds: it will be the first new hospital that Lesotho has had in 50 years. The deal is 
worth $100 million and was overseen by the IFC.  
 
Netcare is reportedly planning to role out this model, in ESA to Swaziland, Zimbabwe, Zambia 
and the Democratic Republic of the Congo. The model mitigates risks for the private equity 
partner, Netcare. The government will pay the private sector back over eighteen years, as 
Netcare puts it, in return getting a modern, well-maintained and equipped hospital (although by 
that stage the physical infrastructure will have aged). Netcare acknowledges that attracting good 
personnel to work in the hospital will be a challenge but expects to pay better salaries to attract 
such staff. Although the return on investment will be lower than for an entirely private venture, 
one of the benefits to Netcare is boosting its social responsibility image, particularly as it has 
been accused, along with other private hospital groups, of helping to push health care costs up in 
South Africa. It is also possible that this public-private partnership provides a platform for the 
company to expand into other countries in the region as well as mitigate some of the risks 
normally faced by new private ventures. 
 
The PharmAccess Foundation 
Sources: Van der Gaag and Gustafsson-Wright 2007; Pharmaccess Foundation 2011 
 
PharmAccess is a Dutch NGO that was established in 2004, initially to facilitate HAART access 
and develop HIV/AIDS programmes in Africa. It has always worked closely with the private 
sector, especially through designing and implementing workplace-based programmes. It has 
since become involved in the delivery of general care and has a particular interest in the 
provision and financing of this care through private health insurance mechanisms. PharmAccess 
now also facilitates investment in the African health sector. It co-founded the Health Insurance 
Fund in 2005 and, in 2007, the related Investment Fund for Health in Africa. It also manages the 
Health Insurance Fund and the Medical Credit Fund. 
 
PharmAccess is active in many countries in the region. It has a two-pronged strategy. Firstly, it 
aims to stimulate the demand for health care by improving quality and subsidising access to 
private health insurance (through the Health Insurance Fund). Second, it aims to stimulate the 
supply of health care through providing private equity and debt financing for health care providers 




Investment Fund for Health in Africa and Medical Credit Fund in particular). External funding 
provided through the Health Insurance Fund is supposed to stimulate investment in the 
Investment Fund for Health in Africa as the risk to private investors is reduced through the 
stimulation of demand for insurance and health care. The role of PharmAccess is to provide 
technical support in developing programmes, setting up contracts with providers etc. The 
Brookings Institute is involved in researching components of the programmes developed by 
PharmAccess.  
 
Shelys Africa Limited 
Extracted from: Mhamba and Mbirigenda 2010: 12-13 
‘Shelys Pharmaceutical was established in Tanzania in 1984 when Tanzania embarked on its 
liberalisation policy and allowed private investors to invest in industrial production. Shelys Africa 
Limited is the holding company of a group of east African pharmaceutical companies (‘the Shelys 
Group’), with major industrial operations in Tanzania (Shelys Pharmaceuticals) and Kenya (Beta 
Healthcare International) … Shelys’ manufacturing facility in Dar-es-Salaam is capable of 
manufacturing solids, liquids, capsules and penicillin, and its product portfolio includes: pain and 
fever management, coughs and cold, anti-malarials, antibiotics, antimicrobials and 
contraceptives. Beta Healthcare has its origins in the British Boots International and joined the 
Shelys Group in 2003. Its product portfolio comprises mostly over-the-counter drugs and a few 
branded pharmaceutical products. Beta Healthcare’s domestic customer base is spread 
throughout Kenya, and export sales are generated in east and central Africa, including Tanzania, 
Uganda, Rwanda and Congo … 
 
Aspen Pharmacare Holdings Limited - a South African Pharmaceutical company listed on the 
Johannesburg Stock Exchange - acquired 60% of the share capital of Shelys Africa Limited in 
2008 … Capital flow from Aspen Holdings to Shelys Pharmaceutical industry has been used to 
upgrade the company’s manufacturing capability to produce solids, liquids, capsules and 
penicillin … 
 
Although Shelys/Aspen is the leading supplier of locally produced essential medicines in 
Tanzania, it does not have an explicit policy or strategy focused on meeting the needs of the 
poor by providing access to essential medicines through local production and/or affordable 
pricing. A decreasing share of Shelys Pharmaceutical products are now marketed in Tanzania 
(from 65% in 2008 to 59% in 2009), due to increased export to new markets (e.g. Rwanda and 
Democratic Republic of Congo) and a larger share of export to Zambia …’ 
 
Strategis Insurance (Tanzania) Limited 
Extracted from: International Finance Corporation 2007: 71 
 
Strategis Insurance (Tanzania) Limited was the first private specialist health insurer to be 
registered in Tanzania in March 2003 (Health Insurance Fund 2010).  
 
‘Tanzania’s leading private insurer, Strategis has experienced rapid growth from corporate 
subscribers, and has set aggressive growth targets for underwriting large insurance funds, more 
local companies, and individuals. 
 
 Strategis offered the first private health insurance in Tanzania. It designs, underwrites, and 
sells medical insurance to: 
– Companies 
– Affinity groups 
– Families and individuals 
– Travel cover (in/out) 
 Three percent profit before tax, almost exclusively from underwriting given limited investment 
income opportunities. 




 Network of > 100 contracted private providers throughout the country. 
 Quality standards part of provider contract, but hard to enforce if no alternative 
 provider is available. 
 Expatriate management provided through AMSCO project (funded by UN and IFC). 
 30,000 of Tanzania’s 60,000–70,000 insured lives. 
 … Strategis has experienced rapid growth from corporate subscribers… 
 Four year old company with 2005–2006 subscriber growth of ~50%. 
 Past growth driven by corporate accounts (first multinational corporations, then local 
companies). 
 …and has set aggressive growth targets for underwriting large insurance funds, medium-
sized enterprises and individuals. 
 Growth targets of doubling underwriting in 2007 and 50% growth in 2008. 
 Strategis has tendered for new Dutch Health Insurance Fund contract to insure large, 
generally non-wealthy population. 
 Corporate insurance continues to offer near term growth with good margins. 
 Retail growth opportunity in medium-term, given growth in employed families seeking quality 
care. 
– Currently <10% retail, with 30% target 
– First local company with individual risk assessment capability for retail underwriting. Able 
to partner with affinity groups and banks for retail volume. 
 Key growth challenges include: 
– Competition from new entrants for both subscribers and personnel. 
– Uncertain regulatory environment: New legislation expected on HMOs may have 
consequences for registered insurers. 
– Uncertain impact of National Health Insurance Fund’s aspiration of growing coverage to 





Equity in health implies addressing differences in health status that are unnecessary, 
avoidable and unfair. In southern Africa, these typically relate to disparities across racial 
groups, rural/urban status, socio-economic status, gender, age and geographical region. 
EQUINET is primarily concerned with equity motivated interventions that seek to allocate 
resources preferentially to those with the worst health status (vertical equity). EQUINET 
seeks to understand and influence the redistribution of social and economic resources for 
equity oriented interventions, EQUINET also seeks to understand and inform the power and 
ability people (and social groups) have to make choices over health inputs and their capacity 
to use these choices towards health.  
 
 
EQUINET implements work in a number of areas identified as central to health equity in east 
and southern Africa  
 Protecting health in economic and trade policy  
 Building universal, primary health care  oriented health systems 
 Equitable, health systems strengthening responses to HIV and AIDS 
 Fair Financing of health systems  
 Valuing and retaining health workers  
 Organising participatory, people centred health systems 
 Social empowerment and action for health 
 Monitoring progress through country and regional equity watches 
 
 
EQUINET is governed by a steering committee involving institutions and individuals  
co-ordinating theme, country or process work in EQUINET from the following institutions: 
TARSC, Zimbabwe; CWGH, Zimbabwe; University of Cape Town (UCT), South Africa; 
Health Economics Unit, Cape Town, South Africa; MHEN Malawi; HEPS Uganda, University 
of  Limpopo, South Africa,  University of Namibia; University of Western Cape, SEATINI, 
Zimbabwe; REACH Trust Malawi;  Min of Health Mozambique; Ifakara Health Institute, 
Tanzania, Kenya Health Equity Network; and SEAPACOH 
 
 
For further information on EQUINET please contact the secretariat: 
Training and Research Support Centre (TARSC) 
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